Lina Badimon, MD, Barcelona, explains why blocking inflammation may have significant clinical benefit, as inflammation is important in plaque formation. The results of CANTOS can be the dawn of a new era of CV prevention.

Educational information

The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.

These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.

Disclosures

Prof. Lina Badimon is the Director of the Cardiovascular Science Institute (ICCC) in Barcelona in the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.

This recording was developed under auspices of PACE-CME. The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding to produce this expert opinion was provided by an unrestricted educational grant from Novartis.

Pulse aquí para ver este video en Español See more Inflammation Expert Opinions